Skip to main content
SpringerLink
Log in

Quantitative synthesis of the association between the cytochrome P450 1A1 Ile462Val polymorphism and prostate cancer risk

  • Research Article
  • Published:
Tumor Biology

Abstract

The association between the cytochrome P450 1A1 (CYP1A1) Ile462Val polymorphism and prostate cancer risk remains inconclusive owing to the conflicting findings from previous studies. To get a more precise estimate of the possible association, we performed the present meta-analysis. We searched the PUBMED, EMBASE, and Wanfang databases for the studies which met the inclusion criteria. The pooled odds ratio (OR) with corresponding 95 % confidence interval (95 % CI) was used to estimate the association between CYP1A1 Ile462Val polymorphism and prostate cancer risk. A total of 13 studies with 2,350 cases and 2,992 controls were included in the meta-analysis. The results indicated that there was an obvious association between CYP1A1 Ile462Val polymorphism and increased risk of prostate cancer (for Val versus Ile: OR = 1.27, 95 % CI 1.13–1.43, P < 0.001; for ValVal versus IleIle: OR = 1.51, 95 % CI 1.14–2.01, P = 0.004; for ValVal + ValIle versus IleIle: OR = 1.31, 95 % CI 1.14–1.51, P < 0.001; for ValVal versus IleIle + ValIle: OR = 1.38, 95 % CI 1.05–1.81, P = 0.020). Subgroup analyses by ethnicity suggested that CYP1A1 Ile462Val polymorphism was associated with prostate cancer risk in Asians but not in Caucasians. This meta-analysis suggests that there is an association between CYP1A1 Ile462Val polymorphism and increased risk of prostate cancer. More studies with large sample are needed to further assess the association in Caucasians.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Damber JE, Aus G. Prostate cancer. Lancet. 2008;371:1710–21.

    Article  PubMed  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  3. Witte JS. Prostate cancer genomics: towards a new understanding. Nat Rev Genet. 2009;10:77–82.

    Article  PubMed  CAS  Google Scholar 

  4. Risbridger GP, Davis ID, Birrell SN, Tilley WD. Breast and prostate cancer: more similar than different. Nat Rev Cancer. 2010;10:205–12.

    Article  PubMed  CAS  Google Scholar 

  5. Nebert DW, Jones JE. Regulation of the mammalian cytochrome P1-450 (CYP1A1) gene. Int J Biochem. 1989;21:243–52.

    Article  PubMed  CAS  Google Scholar 

  6. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol. 1993;14:77–87.

    Article  PubMed  CAS  Google Scholar 

  7. Lourenco GJ, Silva EF, Rinck-Junior JA, Chone CT, Lima CS. CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma. Tumour Biol. 2011;32:1209–15.

    Article  PubMed  CAS  Google Scholar 

  8. Nebert DW, Petersen DD, Puga A. Human ah locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics. 1991;1:68–78.

    Article  PubMed  CAS  Google Scholar 

  9. Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer. 2009;9:187.

    Article  PubMed  Google Scholar 

  10. Yang S, Jia C, Zhu H, Han S. CYP1A1 Ile462Val polymorphism and cervical cancer: evidence from a meta-analysis. Tumour Biol. 2012;33:2265–72.

    Article  PubMed  CAS  Google Scholar 

  11. Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, et al. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett. 2001;165:171–7.

    Article  PubMed  CAS  Google Scholar 

  12. Beer TM, Evans AJ, Hough KM, Lowe BA, McWilliams JE, Henner WD. Polymorphisms of GSTP1 and related genes and prostate cancer risk. Prostate Cancer Prostatic Dis. 2002;5:22–7.

    Article  PubMed  CAS  Google Scholar 

  13. Suzuki K, Matsui H, Nakazato H, Koike H, Okugi H, Hasumi M, et al. Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: a case-control study. Cancer Lett. 2003;195:177–83.

    Article  PubMed  CAS  Google Scholar 

  14. Aktas D, Hascicek M, Sozen S, Ozen H, Tuncbilek E. CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population. Cancer Genet Cytogenet. 2004;154:81–5.

    Article  PubMed  CAS  Google Scholar 

  15. Guan TY, Li M, Na YQ. [Polymorphism of metabolic gene and genetic susceptibility to prostate cancer]. Zhonghua Wai Ke Za Zhi. 2005;43:1467–70.

    PubMed  Google Scholar 

  16. Nock NL, Liu X, Cicek MS, Li L, Macarie F, Rybicki BA, et al. Polymorphisms in polycyclic aromatic hydrocarbon metabolism and conjugation genes, interactions with smoking and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:756–61.

    Article  PubMed  CAS  Google Scholar 

  17. Yang J, Qian LX, Wu HF, Xu ZQ, Sui YG, Wang XR, et al. Genetic polymorphisms in the cytochrome P450 1A1 and 2E1 genes, smoking, drinking and prostate cancer susceptibility: a case-control study in a Han nationality population in Southern China. Int J Urol. 2006;13:773–80.

    Article  PubMed  CAS  Google Scholar 

  18. Berndt SI, Chatterjee N, Huang WY, Chanock SJ, Welch R, Crawford ED, et al. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:165–8.

    Article  PubMed  CAS  Google Scholar 

  19. Kumar V, Yadav CS, Singh S, Goel S, Ahmed RS, Gupta S, et al. CYP 1A1 polymorphism and organochlorine pesticides levels in the etiology of prostate cancer. Chemosphere. 2010;81:464–8.

    Article  PubMed  CAS  Google Scholar 

  20. Rodrigues IS, Kuasne H, Losi-Guembarovski R, Fuganti PE, Gregorio EP, Kishima MO, et al. Evaluation of the influence of polymorphic variants CYP1A1 2B, CYP1B1 2, CYP3A4 1B, GSTM1 0, and GSTT1 0 in prostate cancer. Urol Oncol. 2011;29:654–63.

    Article  PubMed  CAS  Google Scholar 

  21. Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21:1539–58.

    Article  PubMed  Google Scholar 

  22. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.

    PubMed  CAS  Google Scholar 

  23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    Article  PubMed  CAS  Google Scholar 

  24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    Article  PubMed  CAS  Google Scholar 

  25. Caceres DD, Iturrieta J, Acevedo C, Huidobro C, Varela N, Quinones L. Relationship among metabolizing genes, smoking and alcohol used as modifier factors on prostate cancer risk: exploring some gene-gene and gene-environment interactions. Eur J Epidemiol. 2005;20:79–88.

    Article  PubMed  Google Scholar 

  26. Quinones LA, Irarrazabal CE, Rojas CR, Orellana CE, Acevedo C, Huidobro C, et al. Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study. Asian J Androl. 2006;8:349–55.

    Article  PubMed  CAS  Google Scholar 

  27. Silig Y, Pinarbasi H, Gunes S, Ayan S, Bagci H, Cetinkaya O. Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population. Cancer Invest. 2006;24:41–5.

    Article  PubMed  CAS  Google Scholar 

  28. Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:1869–80.

    Article  PubMed  CAS  Google Scholar 

  29. Koutros S, Berndt SI, Sinha R, Ma X, Chatterjee N, Alavanja MC, et al. Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. Cancer Res. 2009;69:1877–84.

    Article  PubMed  CAS  Google Scholar 

  30. Souiden Y, Mahdouani M, Chaieb K, Bakhrouf A, Mahdouani K. Lack of association of CYP1A1 polymorphism with prostate cancer susceptibility of Tunisian men. Genet Test Mol Biomarkers. 2012;16:661–6.

    Article  PubMed  CAS  Google Scholar 

  31. Holt SK, Kwon EM, Fu R, Kolb S, Feng Z, Ostrander EA, et al. Association of variants in estrogen-related pathway genes with prostate cancer risk. Prostate. 2013;73:1–10.

    Article  PubMed  CAS  Google Scholar 

  32. Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA, Wiley KE, et al. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int J Cancer. 2003;106:375–8.

    Article  PubMed  CAS  Google Scholar 

  33. Gao JP, Huang YD, Yang GZ, Yang YQ. Relationship between genetic polymorphisms of metabolizing enzymes and prostate cancer. National Journal OF Andrology. 2003;9:32–5.

    PubMed  CAS  Google Scholar 

  34. Li M, Guan TY, Li Y, Na YQ. Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men. Chin Med J (Engl). 2008;121:305–8.

    CAS  Google Scholar 

  35. Otsuka T, Iguchi K, Fukami K, Ishii K, Usui S, Sugimura Y, et al. Androgen receptor W741C and T877A mutations in AIDL cells, an androgen-independent subline of prostate cancer LNCaP cells. Tumour Biol. 2011;32:1097–102.

    Article  PubMed  CAS  Google Scholar 

  36. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Giercksky KE, et al. Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines. Tumour Biol. 2012;33:967–78.

    Article  PubMed  CAS  Google Scholar 

  37. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55:300–18. quiz 323-305.

    Article  PubMed  Google Scholar 

  38. Anwar-Mohamed A, Elbekai RH, El-Kadi AO. Regulation of CYP1A1 by heavy metals and consequences for drug metabolism. Expert Opin Drug Metab Toxicol. 2009;5:501–21.

    Article  PubMed  CAS  Google Scholar 

  39. Huang Q, Deshmukh RS, Ericksen SS, Tu Y, Szklarz GD. Preferred binding orientations of phenacetin in CYP1A1 and CYP1A2 are associated with isoform-selective metabolism. Drug Metab Dispos. 2012;40:2324–31.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Urology Department, The First Affiliated Hospital of Xinxiang Medical University, Healthy Road No. 88, Weihui, Henan, 453100, China

    Guangye Han, Pei Liu, Xinjun Zhang & Feng Zhu

  2. Emergency Department, The First Affiliated Hospital of Xinxiang Medical University, Weihui, 453100, China

    Yanjuan Ma

  3. The Infection Department, The First Affiliated Hospital of Xinxiang Medical University, Weihui, 453100, China

    Xiaoxia Wei

Authors
  1. Guangye Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yanjuan Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoxia Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xinjun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Feng Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guangye Han.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Han, G., Ma, Y., Liu, P. et al. Quantitative synthesis of the association between the cytochrome P450 1A1 Ile462Val polymorphism and prostate cancer risk. Tumor Biol. 34, 1511–1516 (2013). https://doi.org/10.1007/s13277-013-0676-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-0676-4

Keywords

Search

Navigation